NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Forecast, Price & News $1.47 +0.05 (+3.52%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$1.37▼$1.5850-Day Range$1.42▼$2.7652-Week Range$0.61▼$4.19Volume212,210 shsAverage Volume539,958 shsMarket Capitalization$71.99 millionP/E RatioN/ADividend YieldN/APrice Target$6.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Corvus Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside350.7% Upside$6.63 Price TargetShort InterestHealthy3.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.57) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector667th out of 964 stocksPharmaceutical Preparations Industry299th out of 445 stocks 3.4 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.63, Corvus Pharmaceuticals has a forecasted upside of 350.7% from its current price of $1.47.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.78% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently increased by 21.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVS. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Corvus Pharmaceuticals this week, compared to 1 article on an average week.Search Interest58 people have searched for CRVS on MarketBeat in the last 30 days. This is an increase of 115% compared to the previous 30 days.MarketBeat Follows1 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.79% of the stock of Corvus Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.57) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corvus Pharmaceuticals (NASDAQ:CRVS) StockCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Read More CRVS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRVS Stock News HeadlinesSeptember 12, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)September 8, 2023 | fool.comCorvus Pharmaceuticals (NASDAQ: CRVS)September 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 7, 2023 | msn.comCantor Fitzgerald Reiterates Corvus Pharmaceuticals (CRVS) Overweight RecommendationSeptember 6, 2023 | finance.yahoo.comCorvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDAAugust 18, 2023 | markets.businessinsider.comCorvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: OppenheimerAugust 8, 2023 | finance.yahoo.comCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 1, 2023 | msn.comCircling Back On Corvus PharmaceuticalsSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 1, 2023 | finance.yahoo.comCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023July 6, 2023 | finance.yahoo.comCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)June 29, 2023 | finance.yahoo.comCorvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International ConferenceJune 29, 2023 | finance.yahoo.comCorvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International ConferenceJune 15, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)June 15, 2023 | seekingalpha.comAldeyra, Bioventus top healthcare gainers; Mersana, Bone Biologics among losersJune 4, 2023 | finance.yahoo.comIndividual investors among Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) largest shareholders, saw gain in holdings value after stock jumped 23% last weekMay 31, 2023 | finance.yahoo.comCorvus Pharmaceuticals to Present at the Jefferies Healthcare ConferenceMay 30, 2023 | msn.comLadenburg Thalmann Maintains Corvus Pharmaceuticals (CRVS) Buy RecommendationMay 26, 2023 | finance.yahoo.comIs Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?May 17, 2023 | finance.yahoo.comCorvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant LymphomaMay 12, 2023 | seekingalpha.comCorvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma MarketMay 12, 2023 | finance.yahoo.comCorvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's WhyMay 10, 2023 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial ResultsMay 10, 2023 | benzinga.comWhy Are Corvus Pharmaceuticals Trading Higher TodayMay 9, 2023 | msn.comCantor Fitzgerald Maintains Corvus Pharmaceuticals (CRVS) Overweight RecommendationApril 20, 2023 | finance.yahoo.comCorvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023April 17, 2023 | finance.yahoo.comCorvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual MeetingSee More Headlines Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Company Calendar Last Earnings8/08/2023Today9/26/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.63 High Stock Price Forecast$12.00 Low Stock Price Forecast$3.50 Forecasted Upside/Downside+324.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-71.23% Return on Assets-58.94% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book1.29Miscellaneous Outstanding Shares48,970,000Free Float33,640,000Market Cap$76.39 million OptionableNot Optionable Beta0.98 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Richard A. Miller M.D. (Age 72)Co-Founder, Pres, CEO & Chairman Comp: $306kDr. Peter A. Thompson FACP (Age 63)M.D., Co-Founder & Independent Director Comp: $47kMr. Leiv Lea (Age 69)Chief Financial Officer Comp: $388.73kDr. William Benton Jones Ph.D. (Age 57)Sr. VP of Pharmaceutical Devel. Comp: $346.42kDr. James T. Rosenbaum M.D.Sr. VP of ResearchKey CompetitorsHCW BiologicsNASDAQ:HCWBKronos BioNASDAQ:KRONFibroGenNASDAQ:FGENViveon Health AcquisitionNYSE:VHAQVeruNASDAQ:VERUView All CompetitorsInsiders & InstitutionsTucker Asset Management LLCBought 12,871 shares on 9/8/2023Ownership: 0.026%Wolverine Trading LLCBought 15,400 shares on 8/23/2023Ownership: 0.000%CHI Advisors LLCSold 2,139,402 shares on 8/22/2023Ownership: 0.408%Goldman Sachs Group Inc.Bought 94,311 shares on 8/15/2023Ownership: 0.193%Citadel Advisors LLCBought 21,600 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CRVS Stock - Frequently Asked Questions Should I buy or sell Corvus Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRVS shares. View CRVS analyst ratings or view top-rated stocks. What is Corvus Pharmaceuticals' stock price forecast for 2023? 4 equities research analysts have issued 1-year price objectives for Corvus Pharmaceuticals' stock. Their CRVS share price forecasts range from $3.50 to $12.00. On average, they expect the company's stock price to reach $6.63 in the next year. This suggests a possible upside of 324.7% from the stock's current price. View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts. How have CRVS shares performed in 2023? Corvus Pharmaceuticals' stock was trading at $0.85 at the beginning of the year. Since then, CRVS shares have increased by 83.5% and is now trading at $1.56. View the best growth stocks for 2023 here. Are investors shorting Corvus Pharmaceuticals? Corvus Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,370,000 shares, an increase of 21.2% from the August 15th total of 1,130,000 shares. Based on an average daily trading volume, of 603,300 shares, the days-to-cover ratio is presently 2.3 days. Currently, 3.8% of the company's stock are sold short. View Corvus Pharmaceuticals' Short Interest. When is Corvus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our CRVS earnings forecast. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO? 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO). When did Corvus Pharmaceuticals IPO? (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. What is Corvus Pharmaceuticals' stock symbol? Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS." Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.09%), Renaissance Technologies LLC (1.00%), Geode Capital Management LLC (0.70%), Marshall Wace LLP (0.61%), Towerview LLC (0.44%) and CHI Advisors LLC (0.41%). Insiders that own company stock include Ecor1 Capital, Llc, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Corvus Pharmaceuticals' stock price today? One share of CRVS stock can currently be purchased for approximately $1.56. How much money does Corvus Pharmaceuticals make? Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $76.39 million. The company earns $-41,310,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. How can I contact Corvus Pharmaceuticals? Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com. This page (NASDAQ:CRVS) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.